CD4 and myeloid sarcoma: Thus, we aimed to explore the differences in mtDNA extracted from CD4+ T cells between patients with a recent diagnosis of either Clinically Isolated Syndrome (CIS) or Relapsing–Remitting MS (RRMS) and healthy controls (HC).